DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "EpiCast Report: Venous Thromboembolism - Epidemiology Forecast to 2026" drug pipelines to their offering.
"EpiCast Report: Venous Thromboembolism - Epidemiology Forecast to 2026" provides an overview of the risk factors, comorbidities, and the global and historical trends for VTE in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
It includes a 10-year epidemiological forecast for the diagnosed incident cases of PE, DVT, and VTE, as well as the number of VTE attacks, the number of medically ill discharges that are at risk for VTE, the number of primary total knee replacements and revisions, and the number of hip replacements, each of which are segmented by sex and age.
Additionally, it includes a forecast for the number of recurrent VTE cases at one and 10 years after the incident event, and the number of diagnosed VTE cases with cancer as comorbidity.
Key Topics Covered:
1 Table of Contents
2 Venous Thromboembolism: Executive Summary
3 Introduction
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.5 Epidemiological Forecast for VTE (2016-2026)
3.5.1 Diagnosed Incident Cases of Pulmonary Embolism
3.5.2 Diagnosed Incident Cases of Deep Vein Thrombosis
3.5.3 Diagnosed Incident Cases of VTE
3.5.4 Age-Specific Diagnosed Incident Cases of VTE
3.5.5 Sex-Specific Diagnosed Incident Cases of VTE
3.5.6 One- and 10-Year First Time Recurrent Cases of VTE
3.5.7 Number of VTE Cases with Cancer as Comorbidity
3.5.8 Number of VTE Attacks
3.5.9 Number of Hospital Discharges Meeting Criteria for Medically Ill and Those at Risk for VTE
3.5.10 Number of Primary Total Knee Replacements and Revisions
3.5.11 Number of Hip Replacements
3.6 Discussion
4 Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/7nc6bq/epicast_report
